Amlodipine Besylate And Olmesartan Medoxomil

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.

Amlodipine may increase systemic exposure of cyclosporine. Frequent monitoring of trough blood levels and dose adjustment recommended.

Olmesartan increases serum lithium concentrations and may cause lithium toxicity.

Dual blockade of RAS is associated with increased risks of hypotension, hyperkalemia, and acute renal failure compared to monotherapy.

NSAIDs may deteriorate renal function, cause acute renal failure, and attenuate antihypertensive effect of olmesartan. Monitor renal function periodically.

May result in deterioration of renal function, acute renal failure, and attenuation of antihypertensive effect of olmesartan. Monitor renal function periodically.

Co-administration increases systemic exposure of simvastatin. Limit simvastatin dose to 20 mg daily in patients on amlodipine.

Amlodipine may increase systemic exposure of tacrolimus. Frequent monitoring of trough blood levels and dose adjustment recommended.

7 DRUG INTERACTIONS Amlodipine ( 7.1 ): • If simvastatin is co-administered with amlodipine, do not exceed 20 mg daily of simvastatin. • Increased exposure of amlodipine when coadministered with CYP3A inhibitors Olmesartan medoxomil ( 7.2 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. 7.1 Drug Interactions with Amlodipine Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin.

Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose.

Co-administration with amlodipine may reduce amlodipine efficacy. Closely monitor blood pressure when co-administered.

Olmesartan medoxomil ( 7.2 ): Nonsteroidal anti-inflammatory drugs (NSAIDS) may lead to increased risk of renal impairment and loss of antihypertensive effect. Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. 7.2 Drug Interactions with Olmesartan Medoxomil Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure.

Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. Use with Colesevelam Hydrochloride: Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan. Administration of olmesartan at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect.